• Explore /
  • Poster
  • / Long-term follow-up of a phase Ib trial of idelalisib (IDELA) in combination with chemoimmunotherapy (CIT) in patients (pts) with relapsed/refractory (R/R) CLL including pts with del17p/<em>TP53</em> mutation.

Long-term follow-up of a phase Ib trial of idelalisib (IDELA) in combination with chemoimmunotherapy (CIT) in patients (pts) with relapsed/refractory (R/R) CLL including pts with del17p/TP53 mutation.

Abstract Poster

Authors

null

Jacqueline Claudia Barrientos

Hofstra North Shore - LIJ School of Medicine, New Hyde Park, NY

Jacqueline Claudia Barrientos , Steven Coutre , Sven De Vos , Ian Flinn , Nina D. Wagner-Johnston , Marshall T. Schreeder , Jeff Porter Sharman , Thomas E. Boyd , Kanti Roop Rai , John Leonard , Bess Sorensen , Anthony Viggiano , Thomas Michael Jahn , Richard R. Furman

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Leukemia, Myelodysplasia, and Transplantation

Track

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Sub Track

Leukemia

Clinical Trial Registration Number

NCT01088048

Citation

J Clin Oncol 33, 2015 (suppl; abstr 7011)

DOI

10.1200/jco.2015.33.15_suppl.7011

Abstract #

7011

Poster Bd #

1

Abstract Disclosures

Similar Posters

First Author: Jeffrey Alan Jones

First Author: Jennifer R. Brown

First Author: Wojciech Jurczak

Poster

2014 ASCO Annual Meeting

Second interim analysis of a phase 3 study evaluating idelalisib and rituximab for relapsed CLL.

Second interim analysis of a phase 3 study evaluating idelalisib and rituximab for relapsed CLL.

First Author: Steven E. Coutre